Skip to content
Disclosery

Saturn V Capital Management LP

Follow

13F filer, CIK 1964437, AUSTIN, TX

Saturn V Capital Management LP reported $544,900,849 across 20 holdings for the quarter ended 2025-12-31, in a 13F-HR filed 2026-02-17. Its ten largest share positions make up 76.47% of the portfolio.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001964437-26-000003

Period
2025-12-31
Reported value
$545M
Holdings
20
Top 10 weight
76.47%
New
8
Sold out
5

Largest buys vs the previous quarter

SecurityShares changeApprox. value
ALMSnew+3,135,953$30.6M
XFORnew+5,800,530$23.2M
IVVDnew+7,735,386$19.1M
IMMXnew+2,999,169$15.7M
MNPRadded+170,331$11.1M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
COGTreduced-807,977-$28.7M
CGONexited-579,895-$23.4M
ABVXreduced-152,045-$20.5M
XENEexited-503,701-$20.2M
MERUS N Vexited-184,135-$17.3M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q4 2025

Share positions as resolved from 13F-HR 0001964437-26-000003, largest first. % of portfolio is the value over $544,900,849, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
ABVXABIVAX SAQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 648,019 shares; 2024Q4: 653,071 shares; 2025Q1: 552,926 shares; 2025Q2: 622,479 shares; 2025Q3: 801,224 shares; 2025Q4: 649,179 shares 649,179$87.5M16.07%-152,045Timeline
AMLXAMYLYX PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: 889,073 shares; 2025Q1: 2,426,436 shares; 2025Q2: 3,260,570 shares; 2025Q3: 4,604,878 shares; 2025Q4: 4,496,487 shares 4,496,487$54.3M9.97%-108,391Timeline
COGTCOGENT BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 1,712,899 shares; 2024Q4: 1,498,425 shares; 2025Q1: 1,480,020 shares; 2025Q2: 2,297,524 shares; 2025Q3: 2,025,041 shares; 2025Q4: 1,217,064 shares 1,217,064$43.2M7.93%-807,977Timeline
JAZZJAZZ PHARMACEUTICALS PLCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 206,952 shares; 2025Q3: 300,610 shares; 2025Q4: 248,070 shares 248,070$42.2M7.74%-52,540Timeline
PCVXVAXCYTE INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 204,987 shares; 2024Q4: 204,285 shares; 2025Q1: 232,295 shares; 2025Q2: 544,221 shares; 2025Q3: 788,441 shares; 2025Q4: 798,940 shares 798,940$36.9M6.77%+10,499Timeline
DYNDYNE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 1,455,429 shares; 2025Q3: 2,674,469 shares; 2025Q4: 1,788,616 shares 1,788,616$35M6.42%-885,853Timeline
PHVSPHARVARIS N VQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 886,332 shares; 2025Q4: 1,140,033 shares 1,140,033$31.6M5.81%+253,701Timeline
CELCCELCUITY INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 946,335 shares; 2024Q4: 1,063,783 shares; 2025Q1: 1,093,677 shares; 2025Q2: 1,185,520 shares; 2025Q3: 473,828 shares; 2025Q4: 317,095 shares 317,095$31.6M5.8%-156,733Timeline
ALMSALUMIS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 3,135,953 shares 3,135,953$30.6M5.62%newTimeline
IRONDISC MEDICINE INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 511,041 shares; 2024Q4: 509,406 shares; 2025Q1: 518,177 shares; 2025Q2: 396,115 shares; 2025Q3: 340,897 shares; 2025Q4: 298,429 shares 298,429$23.7M4.35%-42,468Timeline
XFORX4 PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 5,800,530 shares 5,800,530$23.2M4.26%newTimeline
MNPRMONOPAR THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 155,370 shares; 2025Q4: 325,701 shares 325,701$21.3M3.9%+170,331Timeline
IVVDINVIVYD INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 7,735,386 shares 7,735,386$19.1M3.51%newTimeline
OCULOCULAR THERAPEUTIX INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: 191,456 shares; 2025Q1: 598,191 shares; 2025Q2: 728,576 shares; 2025Q3: 1,151,686 shares; 2025Q4: 1,504,880 shares 1,504,880$18.3M3.35%+353,194Timeline
IMMXIMMIX BIOPHARMA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 2,999,169 shares 2,999,169$15.7M2.88%newTimeline
OCSOCULIS HOLDING AGQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 516,761 shares 516,761$10.3M1.89%newTimeline
IKTINHIBIKASE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 3,856,799 shares 3,856,799$7.91M1.45%newTimeline
CNTACENTESSA PHARMACEUTICALS PLCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: 448,692 shares; 2025Q2: 793,327 shares; 2025Q3: 734,539 shares; 2025Q4: 282,692 shares 282,692$7.07M1.3%-451,847Timeline
OVIDOVID THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 2,500,000 shares 2,500,000$4.08M0.75%newTimeline
IVAINVENTIVA SAQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 283,166 shares 283,166$1.32M0.24%newTimeline

Sold out in Q4 2025

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
CGONCG ONCOLOGY INC579,895$23.4Mshares
XENEXENON PHARMACEUTICALS INC503,701$20.2Mshares
MERUS N VMERUS N V184,135$17.3Mshares
LENZLENZ THERAPEUTICS INC368,176$17.1Mshares
NAMSNEWAMSTERDAM PHARMA COMPANY153,147$4.36Mshares

How Q4 2025 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001964437-26-000003 base2026-02-17acceptance time not in the bulk data set